Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study).
- Author:
Eun Soo KIM
1
;
Kyeong Ok KIM
;
Byung Ik JANG
;
Chang Kyun LEE
;
Hyo Jong KIM
;
Kang Moon LEE
;
You Sun KIM
;
Chang Soo EUN
;
Sung Ae JUNG
;
Suk Kyun YANG
;
Jun LEE
;
Tae Oh KIM
;
Yunho JUNG
;
Geom Seog SEO
;
Soon Man YOON
Author Information
1. Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
- Publication Type:Original Article
- Keywords:
Crohn disease;
Infliximab;
Adalimumab;
Preference
- MeSH:
Crohn Disease*;
Humans;
Korea;
Logistic Models;
Male;
Necrosis*;
Patient Preference;
Prospective Studies;
Tertiary Care Centers
- From:Gut and Liver
2016;10(3):391-398
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Two comparable anti-tumor necrosis factor (TNF) agents with different routes of administration (intravenous [iv] infliximab [IFX] vs subcutaneous [sc] adalimumab [ADA]) are available for patients with Crohn's disease (CD) in Korea. This study aimed to identify the preferences of Korean CD patients for a specific anti-TNF agent and the factors contributing to the decision. METHODS: A prospective survey was performed among anti-TNF-naive CD patients in 10 tertiary referral hospitals. A 16-item questionnaire addressed patient preferences and the factors contributing to the decision in favor of a particular anti-TNF agent. A logistic regression was conducted to assess predictive factors for ADA preference. RESULTS: Overall, 189 patients (139 males; mean age, 32.47±11.71 years) completed the questionnaire. IFX and ADA were preferred by 63.5% (120/189) and 36.5% (69/189) of patients, respectively. The most influential reason for choosing IFX was ‘doctor's presence' (68.3%, 82/120), and ADA was “easy to use” (34.8%, 24/69). Amid various clinicodemographic data, having a >60-minute travel time to the hospital was a significant independent predictive factor for ADA preference. CONCLUSIONS: A large number of anti-TNF-naive Korean patients with CD preferred anti-TNFs with an iv route of administration. The reassuring effect of a doctor's presence might be the main contributing factor for this decision.
